SHARE NOW
MicrofluidX will be testing its Cyto EngineTM‘s capabilities using high-quality, ethically sourced starting materials provided by Anthony Nolan.
“We’re very excited to work with the expert team at Anthony Nolan who understand our needs completely,” commented Antoine Espinet, CEO at MicrofluidX.
Anthony Nolan’s Cell Therapy and Laboratory Services have become renowned for sourcing and supplying donor starting materials to the cell and gene therapy industry, helping to transform the life sciences industry. The cells provided by Anthony Nolan for use in this research will be donated by healthy, consenting adult donors for research and manufacturing.
“By partnering with Anthony Nolan we know that the cells we are using to develop our technologies are ethically sourced and of the highest quality,” continued Espinet.
MicrofluidX is a UK-based developer of an innovative bioreactor platform, Cyto EngineTM, designed to address the disconnects between cell biology research and industrialized cell therapy manufacturing. The Cyto EngineTM bioreactors use the principles of microfluidics to seamlessly scale from small-volume research tools to GMO manufacturing capabilities, accelerating the development of next-generation cell and gene therapies.
How are you enjoying this news article? Let us know your thoughts, here >>
“As we begin testing the Cyto EngineTM‘s capabilities with our early access partners manufacturing processes we knew we needed a reliable partner to supply the starting material,” said Espinet.
The results from this development will be able to demonstrate the potential benefits MicrofluidX’s bioprocessing technology can bring to accelerate the development and translation of new cell and gene therapies to clinical trials at a significantly lower cost than what current tools can enable.
“Our partnership with MicrofluidX represents a major step in achieving our organisational aim of equity. Our work looks to ensure all patients have the best access to treatment for blood cancers or blood disorders, regardless of background or circumstance. We are optimistic and excited at the prospect of more cost-effective therapies resulting from MicrofluidX’s research, making treatment more accessible for all,” stated Daniel Gibson, Director of Cell & Gene Therapy Services at Anthony Nolan.
Source: Anthony Nolan Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
